Clinical trial of novel brain cancer vaccine in progress at NYUNovember 14th, 2007 - 2:36 am ICT by admin
The vaccine, called DCVax-Brain, includes proteins found in patients’ tumors and is designed to hit cancer cells containing these proteins.
The study underway at NYU Medical Center is an extension of an earlier phase I trial of the vaccine, made by the Northwest Biotherapeutics, Inc., based in Bothell, Washington.
“We are really excited about the promise of this vaccine. Everything now depends on something in addition to surgery so that these tumors do not recur. A cancer vaccine like this may make a difference in extending life and maintaining a good quality of life,” said Patrick J. Kelly, M.D., the chairman of the Department of Neurosurgery and the Joseph Ransohoff Professor of Neurosurgery at NYU School of Medicine.
NYU neuro-oncologist Michael Gruber, M.D. seconded the opinion, saying, “This is a form of individualized therapy. There is a lot of promise with this approach.”
A brain cancer vaccine is intended as a kind of immunotherapy, which means that it primes the patient’s own immune system to kill proteins found in cancer cells.
The trial will enroll patients 18 to 65 years old with newly diagnosed glioblastoma multiforme brain cancer who will receive standard primary treatment with surgery followed by radiation with concurrent chemotherapy. Enrolled patients will be randomized to receive the standard of care, and others will receive the standard of care and the vaccine.
he vaccine will be made from the tumors and immune cells of each patient. When a patient’s tumor is removed during surgery it will be shipped to a laboratory where the tumor cells will be broken up to prepare the first component of the vaccine.
Separately, patients’ dendritic cells, a powerful type of immune cell, will be obtained and sent to a laboratory for purification. Dendritic cells may be able to teach the immune system to recognize and destroy cancer cells. The patients’ tumor cell material is combined with the dendritic cells to form the vaccine. (ANI)
- Vaccine extends life of brain cancer patients - Apr 19, 2012
- Molecule able to fight brain cancer found - Apr 22, 2011
- New procedure busts deadly brain tumour cells - Feb 06, 2012
- Scientists use patient's tumor to form cancer vaccine - Nov 25, 2010
- Mechanism that helps brain cancer evade immune system attack discovered - Jan 16, 2010
- 'Allergies linked to lower risk of brain tumours' - Aug 06, 2012
- 'Smart' lung cancer drug shows promise - Oct 28, 2010
- Vitamin C hastens brain tumour's death - Feb 20, 2012
- Brain tumour's 'grow-or-go' switch found - Mar 12, 2010
- Discovery could lead to 'next-gen' vaccines - Apr 08, 2012
- Protein that could treat aggressive brain tumour identified - Dec 23, 2009
- Cuba launches world's first lung cancer retardant - Sep 07, 2011
- 'Designer protein' opens new door in cancer research - Aug 04, 2010
- Scientists pinpoint deadly brain tumor's origin - Jan 08, 2011
- How breast cancer cells dodge immune system and survive - Feb 02, 2011
Tags: bothell washington, brain cancer, cancer cells, cancer vaccine, concurrent chemotherapy, dendritic cells, glioblastoma multiforme, immune cell, michael gruber, neurosurgery, northwest biotherapeutics inc, nyu medical center, nyu school of medicine, patrick j kelly, proteins, tumor, tumors, which means that